False-positive mammograms could be an indicator of underlying pathology that could result in breast cancer, according to a study published in the Journal of the National Cancer Institute. Screening mammography is associated with false-positive test results in disease-free women, and those women are usually referred back for routine screening after the initial diagnostic work-up does not reveal cancer. Suspicious findings on screenings leading to false-positives include asymmetric densities, skin thickening or retraction, tumor-like masses, recently retracted nipples or suspicious axillary lymph nodes. It is unknown if women whose mammographic screenings show these results have a higher long-term risk for breast cancer compared to women who initially test negative. In order to determine if women who test false-positive after mammography screenings have a higher risk of developing breast cancer than those who test negative, My von Euler-Chelpin, Ph.
One in eight women will be diagnosed with breast cancer during her lifetime. The earlier cancer is detected, the better the chance of successful treatment and long-term survival. However, early cancer diagnosis is still challenging as testing by mammography remains cumbersome, costly, and in many cases, cancer can only be detected at an advanced stage. A team based in the Dept. of Biomedical Engineering at McGill University's Faculty of Medicine has developed a new microfluidics-based microarray that could one day radically change how and when cancer is diagnosed. Their findings are published in the April issue of the journal Molecular & Cellular Proteomics. For years, scientists have worked to develop blood tests for cancer based on the presence of the Carcinoembryonic Antigen (CEA), a protein biomarker for cancer identified over 40 years ago by McGill's Dr.
Combining two strategies designed to improve the results of cancer treatment - antiangiogenesis drugs and nanomedicines - may only be successful if the smallest nanomedicines are used. A new study from Massachusetts General Hospital (MGH) researchers, appearing in Nature Nanotechnology, finds that normalizing blood vessels within tumors, which improves the delivery of standard chemotherapy drugs, can block the delivery of larger nanotherapy molecules. "We found that vascular normalization only increases the delivery of the smallest nanomedicines to cancer cells, " says Vikash P. Chauhan, of the Steele Laboratory of Tumor Biology in the MGH Radiation Oncology Department, lead author of the report. "We also showed that the smallest nanomedicines are inherently better than larger nanomedicines at penetrating tumors, suggesting that smaller nanomedicines may be ideal for cancer therapy.
The Ohio State University uses two different approaches to visualize circulating tumor cells (CTCs) and other unusual circulating cells, with both epithelial and hematopoietic characteristics in metastatic breast cancer (mBC) for their new research. The researchers presented the study results during a poster session at the American Association for Cancer Research Annual Meeting 2012 in Chicago, Ill. Researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute used immunocytochemistry and flow cytometry in order to examine enriched blood samples taken from individuals suffering from mBC. The study was supported in part by pilot funding from the Ohio State Center for Clinical and Translational Science (CCTS).
It should be possible to significantly improve the response of common cancers to existing "classical" chemotherapy drugs, say scientists at Cold Spring Harbor Laboratory (CSHL), by introducing agents that alter the interaction of cancer cells with their immediate surroundings, called the tumor microenvironment. In research published online in the journal Cancer Cell, CSHL Assistant Professor Mikala Egeblad and her team report using "live" microscopy to observe how cancer cells in mouse tumors react to the widely used chemotherapeutic agent doxorubicin. They found that selective inhibition of two factors that regulate the tumor microenvironment - enzymes called matrix metalloproteinases (MMPs) and a class of immune signaling molecules called chemokines - made breast tumors in mice more responsive to the drug.